Skip to content

EV / EBITDA at other companies

CVS Health logo
CVS HealthCVS
9.2×+2.7×
UnitedHealth Group logo
UnitedHealth GroupUNH
12.8×-1.3×
Astrana Health logo
Astrana HealthASTH
13.8×-0.8×
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
19×+3.3×
Elevance Health logo
Elevance HealthELV
11.8×+0.4×
Privia Health Group, Inc. logo
Privia Health Group, Inc.PRVA
44.7×-33.3×

Other financials

Income statement

See full
Revenue$496.2M+2.6%
Gross profit$83.8M-18.2%
Operating income-$10.6M-553%
Net income-$26.6M+58.8%
EPS (diluted)-$0.24+61.9%

Balance sheet

See full
Cash & equivalents$142.0M-42.4%
Total debt$985.4M+13.3%
Total equity$396.4M-57.6%
Total assets$1.9B-29.2%

Cash flow

See full
Operating cash flow-$984.0K-122%

Valuation

See full
Market cap$565.78M-47.9%
Enterprise value$1.41B-17.6%
P/S0.3×-0.2×

Profitability

See full
Gross margin20.2%+4.9pp
Operating margin-22.2%-23.5pp
Net margin-26.3%-33.2pp
FCF margin-9.7%

Returns & leverage

See full
Return on equity-74.6%-90.1pp
Debt / equity2.5×+1.6×
Current ratio1.3×+0.3×

Where this comes from

Calculated from Evolent Health, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Evolent Health, Inc.’s 10-Q, filed November 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Evolent Health, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Evolent Health, Inc.'s EV / EBITDA?
Evolent Health, Inc. (EVH) reported EV / EBITDA of 24.5× in Q3 2025.
How has Evolent Health, Inc.'s EV / EBITDA changed year-over-year?
Evolent Health, Inc.'s EV / EBITDA decreased by 51.8% year-over-year, from 50.7× to 24.5×.
What is the long-term trend for Evolent Health, Inc.'s EV / EBITDA?
Over 3 years (2021 to 2024), Evolent Health, Inc.'s EV / EBITDA has grown at a -44.3% compound annual growth rate (CAGR), from 141.2× to 24.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.